Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more


Wednesday 19 October 2011

Interactions with rilpivirine and comedications are now available on the website and the HIV iCharts app.  The printable versions of the charts and HIV-Charts2Go have also been updated to include these new interactions.

Rilpivirine is primarily metabolized by cytochrome P450 (CYP)3A - drugs that induce or inhibit CYP3A may affect the clearance of rilpivirine. At the recommended dose of 25 mg once daily, rilpivirine is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.
Rilipivirine was licensed a few months ago by the FDA in the US and has been recommended for approval in Europe by the EMA.  Rilpivirine is marketed as Edurant® and is also available in as a coformulation (Complera®, Eviplera®) with emtricitabine and tenofovir.
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016